centanafadine   Click here for help

GtoPdb Ligand ID: 14621

Synonyms: DOV 216,419 | DOV-216419 | EB-1020 | Simtriyo®
Approved drug PDB Ligand
centanafadine is an approved drug
Compound class: Synthetic organic
Comment: Centanafadine (EB-1020) is a triple monoamine reuptake inhibitor [1-2,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 12.03
Molecular weight 209.29
XLogP 2.46
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC2=C(C=C1)C=C(C=C2)[C@]34C[C@]4([H])CNC3
Isomeric SMILES [C@@]12([C@](C1)(CNC2)[H])C3=CC4=C(C=C3)C=CC=C4
InChI InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
InChI Key HKHCSWPSUSWGLI-CABCVRRESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Centanafadine (EB-1020) was progressed as a clinical candidate, for potential to treat generalized anxiety and attention-deficit hyperactivity disorder (ADHD) [5-6]. First approval was granted by the US FDA in July 2026, to treat ADHD [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06926829 A Long-term Trial of EB-1020 in Adult Patients With ADHD Phase 3 Interventional Otsuka Pharmaceutical Co., Ltd.
NCT06973577 P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Phase 3 Interventional Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT07086313 A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD Phase 2/Phase 3 Interventional Otsuka Pharmaceutical Co., Ltd.
NCT07087327 A Long-term Trial of EB-1020 in Pediatric Patients With ADHD Phase 3 Interventional Otsuka Pharmaceutical Co., Ltd.
NCT05428033 A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) Phase 3 Interventional Otsuka Pharmaceutical Development & Commercialization, Inc. 7
NCT05257265 A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder Phase 3 Interventional Otsuka Pharmaceutical Development & Commercialization, Inc. 7